The introduction of Retatrutide ZPHC, at a strength of 120mg, is generating considerable interest within the weight loss community. This innovative dual GIP and GLP-1 agonist medication appears to provide significant improvements in body reduction compared to current therapies. Preliminary clinical trials have indicated substantial declines in body